Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'

被引:31
|
作者
Lee, Kyu-Sung [12 ]
Lee, Hye Won [12 ]
Choo, Myung-Soo [11 ]
Paick, Jae-Seung [10 ]
Lee, Jeong Gu [9 ]
Seo, Ju Tae [8 ]
Lee, Jeong Zoo [2 ]
Lee, Young-Suk [12 ]
Yoon, Hana [7 ]
Park, Choal Hee [3 ]
Na, Yong-Gil [4 ]
Jeong, Young Beom [5 ]
Lee, Jong Bouk [1 ]
Park, Won Hee [6 ]
机构
[1] Natl Med Ctr, Seoul, South Korea
[2] Pusan Natl Univ, Coll Med, Pusan 609735, South Korea
[3] Keimyung Univ, Sch Med, Taegu, South Korea
[4] Chungnam Natl Univ, Coll Med, Taejon, South Korea
[5] Chonbuk Natl Univ, Sch Med, Jeonju, South Korea
[6] Inha Univ, Coll Med, Inchon, South Korea
[7] Ewha Womans Univ, Sch Med, Seoul, South Korea
[8] Kwandong Univ, Coll Med, Seoul, South Korea
[9] Korea Univ, Coll Med, Seoul 136705, South Korea
[10] Seoul Natl Univ, Coll Med, Seoul, South Korea
[11] Univ Ulsan, Coll Med, Seoul, South Korea
[12] Sungkyunkwan Univ, Dept Urol, Samsung Med Ctr, Sch Med, Seoul, South Korea
关键词
overactive bladder; urinary urgency; propiverine hydrochloride; randomized trial; DOUBLE-BLIND; INCONTINENCE; SYMPTOMS; TOLERABILITY; TOLTERODINE; SOLIFENACIN; PERCEPTION; EFFICACY; TRIAL;
D O I
10.1111/j.1464-410X.2009.09050.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To investigate the effects of a daily regimen of propiverine 20 mg in patients with an overactive bladder (OAB), focused on improving urgency, as the clinical efficacy of treatment for OAB should be measured in terms of urgency, the cornerstone symptom of OAB. PATIENTS AND METHODS Eligible patients aged >= 18 years with symptoms of OAB were enrolled in this multicentre, prospective, parallel, double-blind, placebo-controlled trial. Of 264 patients (mean age 52.2 years), 221 who had efficacy data available from baseline and at least one on-treatment visit with > 75% compliance with medication were analysed (142 in the propiverine group and 79 in the placebo group). All patients were randomized to receive a placebo or 20 mg propiverine once daily in a 12-week study. They completed a 3-day voiding diary before visits during the study period, including the severity of urgency associated with every voiding, using the Indevus Urgency Severity Scale and the Urgency Perception Score. The patients' overall self-evaluation of treatment benefits at the end of the study, and safety data, were also collected. RESULTS The daily urgency episodes reduced significantly from baseline to 12 weeks on propiverine treatment, compared with placebo (-46.0% vs -31.3%, P = 0.005). Secondary endpoints, including sum of urgency severity per 24 h, urgency severity per void, and daytime voiding frequency, were also improved significantly in the propiverine group. Overall, of those patients treated with propiverine, 38.7% rated their treatment as providing 'much benefit', compared with 15.2% of the placebo group (P = 0.025). Adverse events reported by 32 (22.5%) and 10 (12.7%) patients in the propiverine and placebo group were all tolerable. However, this is a short-term study using only one fixed regimen. CONCLUSIONS Propiverine 20 mg once-daily could be an effective treatment for patients with OAB, by improving urgency.
引用
收藏
页码:1565 / 1570
页数:6
相关论文
共 50 条
  • [31] Overactive bladder and urgency urinary incontinence in men undergoing artificial urinary sphincter placement
    Jahromi, Mona S.
    Engle, Kyrra
    Furlong, Daniel
    Guevara Mendez, Alejandra
    Gomez, Christopher S.
    NEUROUROLOGY AND URODYNAMICS, 2020, 39 (05) : 1489 - 1493
  • [32] Development and psychometric evaluation of the urgency questionnaire for evaluating severity and health-related quality of life impact of urinary urgency in overactive bladder
    Coyne, Karin S.
    Sexton, Chris C.
    Thompson, Christine
    Bavendam, Tamara
    Brubaker, Linda
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2015, 26 (03) : 373 - 382
  • [33] A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder
    Park, C.
    Park, J.
    Choo, M-S
    Kim, J. C.
    Lee, J. G.
    Lee, J. Z.
    Lee, K-S
    Kim, D. Y.
    Lee, S-J
    Seo, J. T.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2014, 68 (02) : 188 - 196
  • [34] Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms
    Serels, Scott R.
    Toglia, Marc R.
    Forero-Schwanhaeuser, Sergio
    He, Weizhong
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (10) : 2277 - 2285
  • [35] Review of the Efficacy and Safety of Fesoterodine for Treating Overactive Bladder and Urgency Urinary Incontinence in Elderly Patients
    Adrian Wagg
    Matthias Oelke
    Javier C. Angulo
    David Scholfield
    Daniel Arumi
    Drugs & Aging, 2015, 32 : 103 - 125
  • [36] Evaluation of real-world persistence of propiverine and trospium chloride in treatment of overactive bladder in Germany
    Murgas, Sandra
    Adolf, Daniela
    RESEARCH AND REPORTS IN UROLOGY, 2019, 11 : 9 - 13
  • [37] Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence
    Roehrborn, Claus G.
    Abrams, Paul
    Rovner, Eric S.
    Kaplan, Steven A.
    Herschorn, Sender
    Guan, Zhonghong
    BJU INTERNATIONAL, 2006, 97 (05) : 1003 - 1006
  • [38] Perceptions of "Urgency" in Women With Interstitial Cystitis/Bladder Pain Syndrome or Overactive Bladder
    Clemens, J. Quentin
    Bogart, Laura M.
    Liu, Karin
    Pham, Chau
    Suttorp, Marika
    Berry, Sandra H.
    NEUROUROLOGY AND URODYNAMICS, 2011, 30 (03) : 402 - 405
  • [39] Daily symptom associations for urinary urgency and anxiety, depression and stress in women with overactive bladder
    Allen A. Mehr
    Karl J. Kreder
    Susan K. Lutgendorf
    Patrick Ten Eyck
    Emma S. Greimann
    Catherine S. Bradley
    International Urogynecology Journal, 2022, 33 : 841 - 850
  • [40] Daily symptom associations for urinary urgency and anxiety, depression and stress in women with overactive bladder
    Mehr, Allen A.
    Kreder, Karl J.
    Lutgendorf, Susan K.
    Ten Eyck, Patrick
    Greimann, Emma S.
    Bradley, Catherine S.
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2022, 33 (04) : 841 - 850